| 薛 春,孙新慧.奥美拉唑三联疗法与雷尼替丁三联疗法治疗儿童消化性溃疡疗效对比[J].中国烧伤创疡杂志,2023,(3):240~243. |
| DOI： |
| 中文关键词: 消化性溃疡 奥美拉唑 雷尼替丁 三联疗法 胃肠激素 炎症因子 |
| 英文关键词:Peptic ulcer Omeprazole Ranitidine Triple therapy Gastrointestinal hormones Inflammatory factor |
| 基金项目: |
|
| 摘要点击次数: 1554 |
| 全文下载次数: 4234 |
| 中文摘要: |
| 【摘要】 目的 对比分析奥美拉唑三联疗法与雷尼替丁三联疗法治疗儿童消化性溃疡的临床效果。方法 选取2018年1月至2021年1月西华县人民医院收治的 70 例消化性溃疡患儿作为研究对象, 按照不同治疗方法将其分为奥美拉唑组(35例) 和雷尼替丁组 (35例),奥美拉唑组患儿采用奥美拉唑+阿莫西林+克拉霉素治疗,雷尼替丁组患儿采用雷尼替丁+阿莫西林+克拉霉素治疗, 对比观察两组患儿血清胃肠激素及炎症因子水平、临床疗效与不良反应发生情况。结果 治疗 4 周后, 奥美拉唑组患儿血清胃泌素 (GAS)、胃动素 (MOT) 以及肿瘤坏死因子-α (TNF-α)、白细胞介素-6 ( IL-6)、C 反应蛋白 (CRP) 水平均明显低于雷尼替丁组 ( t = 5.603?6.303、3.938、3.675、3.553, P 均 < 0.001), 生长抑素 ( SST) 水平明显高于雷尼替丁组 ( t = 6.220, P <0.001); 奥美拉唑组患儿中治愈 22 例、好转 11 例、无效 2 例, 明显优于雷尼替丁组患儿的治愈 12 例、好转 15例、无效 8 例 (Z = - 2.628, P = 0.009)。治疗期间, 奥美拉唑组患儿不良反应发生率为 2.86% , 与雷尼替丁组患儿不良反应发生率 11.43% 无明显差异 (χ2= 0.862, P = 0.353)。结论 与雷尼替丁三联疗法相比, 奥美拉唑三联疗法更能明显改善消化性溃疡患儿胃肠激素水平, 降低炎症反应程度, 提高治疗效果。 |
| 英文摘要: |
| 【Abstract】 Objective To compare the clinical efficacy of Omeprazole?based triple therapy and Ranitidine-based triple therapy in the treatment of pediatric peptic ulcer. Methods 70 children with peptic ulcer admitted into Xihua People’s Hospital between January 2018 and January 2021 were enrolled and then divided into Omeprazole group (n = 35) and Ranitidine group (n = 35) based on different treatments they received. Patients in the Omeprazole group were treated with Omeprazole + Amoxicillin + Clarithromycin, while patients in the Ranitidine group were treated with Ranitidine +Amoxicillin + Clarithromycin. The levels of gastrointestinal hormones and inflammatory factors, clinical efficacy and occurrence of adverse reactions were compared between the two groups. Results After 4 weeks of treatment, the levels of serum gastrin (GAS), motilin (MOT), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP) of patients were obviously lower in the Omeprazole group compared with the Ranitidine group ( t = 5.603, 6.303, 3.938,3.675 and 3.553, all P < 0.001), while the level of somatostatin (SST) in the Omeprazole group was markedly higher thanthat in the Ranitidine group ( t = 6.220, P < 0.001). In the Omeprazole group, 22 cases were cured, 11 cases turned better and 2 cases were ineffective, which was significantly superior to the Ranitidine group (Z = - 2.628, P = 0.009) ? 12 cases were cured, 15 cases turned better and 8 cases were ineffective. During the course of treatment, the incidence of adverse reactions was 2.86% in the Omeprazole group, showing no significant difference compared with the corresponding 11.43% in the Ranitidine group ( χ2 = 0.862, P = 0.353). Conclusion Compared with the Ranitidine-based triple therapy, the Omeprazole?based triple therapy can better ameliorate the levels of gastrointestinal hormones of children patients with peptic ulcer, decrease their inflammatory responses, and improve the clinical efficacy. |
|
|
|
|
